For the Inventor, By the Inventor

Enter assignee name

Beijing Hanmi Pharmaceutical Co., Ltd.

USPTO Granted Patents = 13

EPO Patents = 7

Trademarks = 1

Forward Citations = 25

Loading Chart...

Loading Chart...

41 inventors (with patents filed for the assignee):

Maengsup Kim (11 out of 11 patents)

Jiawang Liu (7 out of 11 patents)

Nanmeng Song (6 out of 9 patents)

4. Yaping Yang (6 out of 9 patents)

5. Mi Young Cha (5 out of 5 patents)

6. Gong Li (2 out of 12 patents)

7. Jinming Liu (2 out of 2 patents)

8. Zhanmei Li (2 out of 2 patents)

9. Hongjuan Qiu (2 out of 2 patents)

10. Wenchu Xiao (2 out of 2 patents)

11. Wei Zhang (1 out of 257 patents)

12. Bo Zhang (1 out of 160 patents)

13. Zhenlei Li (1 out of 4 patents)

14. Tao Ma (1 out of 95 patents)

15. Sung Youb Jung (1 out of 62 patents)

13 patents: Sort by Forward Citations

1. 12325743 - Anti-TNFα/anti IL-17A natural antibody structure-like heterodimer form of bispecific antibody and preparation method therefor (2025-06-10),

2. 11827697 - Anti-PD-1/anti-VEGF natural antibody structure like heterodimeric form bispecific antibody and preparation thereof (2023-11-28),

3. 11753471 - Anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and method of preparing same (2023-09-12),

4. 11739151 - Anti-PD-L1/anti-CD47 bispecific antibody (2023-08-29),

5. 11498977 - Heterodimeric immunoglobulin constructs and preparation methods thereof (2022-11-15),

6. 11319378 - Anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same (2022-05-03),

7. 10988482 - IRAK4 inhibitor and use thereof (2021-04-27),

8. 10562902 - IRAK4 inhibitor and use thereof (2020-02-18),

9. 10322108 - N-benzoate group substituted benzopyrroline-2-one derivative and use thereof (2019-06-18),

10. 10273242 - Compound inhibiting activities of BTK and/or JAK3 kinases (2019-04-30),

11. 9840517 - Compound inhibiting activities of BTK and/or JAK3 kinases (2017-12-12),

12. 9789202 - Method for treating cancer using an interferon alpha conjugate (2017-10-17),

13. 9453062 - Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof (2016-09-27),

Beijing Hanmi Pharmaceutical Co., Ltd. is a leading pharmaceutical company specializing in research, development, and production of innovative drugs. Established in 2007, the company has a strong presence in the Chinese pharmaceutical market and is known for its commitment to quality and safety in healthcare. With a focus on cutting-edge technology and scientific research, Hanmi Pharmaceutical continues to make significant contributions to the advancement of medicine and patient care.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

13 Patents

#195 in Beijing

#1,948 in China

#43,679 in the World

Beijing Hanmi Pharmaceutical Co., Ltd.

Forward Citations = 25

41 inventors:

Maengsup Kim (11 out of 11 patents)

Jiawang Liu (7 out of 11 patents)

Nanmeng Song (6 out of 9 patents)

4. Yaping Yang (6 out of 9 patents)

5. Mi Young Cha (5 out of 5 patents)

Please report any incorrect information to support@idiyas.com

Loading…